Multimodal treatment for resectable esophageal cancer

Hiroshi Miyata, Makoto Yamasaki, Yukinori Kurokawa, Shuji Takiguchi, Kiyokazu Nakajima, Yoshiyuki Fujiwara, Masaki Mori, Yuichiro Doki

研究成果: Contribution to journalArticle査読

13 被引用数 (Scopus)

抄録

Surgical resection has been traditionally the mainstay of treatment for localized esophageal cancers. However, survival after surgery alone for advanced esophageal cancer is not satisfactory. In Japan, the development of multimodal therapy for esophageal cancers has centered mainly on systemic chemotherapy plus surgery to control distant metastasis. Based on the results of the recent Japan Clinical Oncology Group (JCOG) 9907 study, preoperative chemotherapy (consisting of 5-FU and cisplatin) followed by surgery has emerged as the standard treatment. In Western countries, where chemoradiotherapy followed by surgery has been mainly explored for patients with resectable esophageal cancers, two large controlled trials that evaluated the effectiveness of preoperative chemotherapy reported conflicting results. However, a recent meta-analysis reported significant survival benefits for preoperative chemotherapy in patients with adenocarcinoma of the esophagus. We need to find new effective preoperative chemotherapeutic regimens, including molecular target agents, with response rates higher than that of the conventional chemotherapy of 5-FU and cisplatin. However, we also must compare the survival benefits of preoperative chemotherapy with preoperative chemoradiotherapy.

本文言語英語
ページ(範囲)461-466
ページ数6
ジャーナルGeneral thoracic and cardiovascular surgery
59
7
DOI
出版ステータス出版済み - 7 2011
外部発表はい

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

フィンガープリント 「Multimodal treatment for resectable esophageal cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル